{"id":1957,"date":"2024-03-03T17:55:00","date_gmt":"2024-03-03T16:55:00","guid":{"rendered":"https:\/\/niho.sk\/?p=1957"},"modified":"2024-04-10T18:03:52","modified_gmt":"2024-04-10T16:03:52","slug":"55-liecivo-empagliflozin-jardiance-na-liecbu-dospelych-pacientov-s-chronickou-chorobou-obliciek","status":"publish","type":"post","link":"https:\/\/www.niho.sk\/en\/55-liecivo-empagliflozin-jardiance-na-liecbu-dospelych-pacientov-s-chronickou-chorobou-obliciek\/","title":{"rendered":"55: Lie\u010divo empaglifloz\u00edn (Jardiance) na lie\u010dbu dospel\u00fdch pacientov s chronickou chorobou obli\u010diek"},"content":{"rendered":"
    \n
  1. Ak\u00e1 je z\u00e1\u0165a\u017e ochorenia pre pacienta? Ako z\u00e1sadn\u00e9 je ochorenie?<\/strong><\/li>\n<\/ol>\n\n\n\n

    Chronick\u00e1 choroba obli\u010diek (CKD) je r\u00f4znorod\u00e1 skupina por\u00fach charakterizovan\u00fdch zmenami v \u0161trukt\u00fare a funkcii obli\u010diek. S\u00fa\u010dasn\u00e1 lie\u010dba sa zameriava na spomalenie progresie ochorenia obli\u010diek a lie\u010dbu komplik\u00e1ci\u00ed. Ochorenie m\u00e1 z\u00e1va\u017en\u00fd vplyv na fyzick\u00fa a emocion\u00e1lnu pohodu pacientov. S progresiou ochorenia vznik\u00e1 u pacientov v\u00e4\u010d\u0161ie riziko kardiovaskul\u00e1rnych a in\u00fdch komplik\u00e1ci\u00ed, v pr\u00edpade zlyhania funkcie obli\u010diek pacienti \u017eij\u00fa na dial\u00fdze alebo absolvuj\u00fa transplant\u00e1ciu obli\u010dky. Aktu\u00e1lne hraden\u00e1 lie\u010dba nezodpoved\u00e1 najnov\u0161\u00edm medzin\u00e1rodn\u00fdm postupom. <\/p>\n\n\n\n

      \n
    1. O ak\u00fd liek ide?<\/strong><\/li>\n<\/ol>\n\n\n\n

      Jardiance obsahuje lie\u010divo empaglifloz\u00edn. Je \u010dlenom skupiny liekov naz\u00fdvan\u00fdch inhib\u00edtory kotransport\u00e9ra pre sod\u00edk a gluk\u00f3zu 2 (SGLT2).<\/p>\n\n\n\n

      Jardiance \u00fa\u010dinkuje tak, \u017ee vo va\u0161ich obli\u010dk\u00e1ch blokuje bielkovinu SGLT2. To sp\u00f4sobuje vylu\u010dovanie cukru (gluk\u00f3zy) z krvi mo\u010dom. Jardiance tak zni\u017euje mno\u017estvo cukru vo va\u0161ej krvi. Tento liek m\u00f4\u017ee tie\u017e pom\u00f4c\u0165 predch\u00e1dza\u0165 ochoreniu srdca u pacientov s cukrovkou 2. typu.<\/p>\n\n\n\n

      Jardiance bol registrovan\u00fd v Eur\u00f3pskej liekovej agent\u00fare v m\u00e1ji 2014.<\/p>\n\n\n\n

        \n
      1. Ako sa na hodnoten\u00e9 lie\u010divo pozeraj\u00fa odborn\u00edci?\u00a0<\/strong><\/li>\n<\/ol>\n\n\n\n

        Klinick\u00fd odborn\u00edk sa vyjadril, \u017ee za pr\u00ednos technol\u00f3gie by pova\u017eoval predch\u00e1dzanie alebo spomalenie progresie ochorenia CKD, zn\u00ed\u017eenie celkovej \u00famrtnosti, zn\u00ed\u017eenie rizika komorbid\u00edt a komplik\u00e1ci\u00ed (vr\u00e1tane dial\u00fdz a transplant\u00e1ci\u00ed) a zn\u00ed\u017eenie hospitaliz\u00e1ci\u00ed. Odborn\u00edk o\u010dak\u00e1va, \u017ee hodnoten\u00e9 lie\u010divo m\u00e1 v\u00fdznamn\u00fd klinick\u00fd pr\u00ednos v porovnan\u00ed so s\u00fa\u010dasnou \u0161tandardnou lie\u010dbou a v\u00fdsledky \u0161t\u00fadie EMPA-KIDNEY, ktor\u00e1 sa venuje lie\u010dbe CKD pomocou hodnotenej technol\u00f3gie, pova\u017euje v prim\u00e1rnom aj sekund\u00e1rnych ukazovate\u013eoch za klinick\u00fd v\u00fdznamn\u00e9 a relevantn\u00e9.<\/p>\n\n\n\n

          \n
        1. \u010co hodnotilo NIHO a ak\u00fd je v\u00fdsledok?<\/strong><\/li>\n<\/ol>\n\n\n\n

          Dr\u017eite\u013e registr\u00e1cie (Boehringer Ingelheim International GmbH (DEU)) podal \u017eiados\u0165 o zaradenie lie\u010diva empaglifloz\u00edn (Jardiance) na lie\u010dbu dospel\u00fdch pacientov s chronickou chorobou obli\u010diek.<\/p>\n\n\n\n

          NIHO odpor\u00fa\u010da vyhovie\u0165 \u017eiadosti o kategorizovanie lieku Jardiance v predmetnej indik\u00e1ci\u00ed, pokia\u013e dr\u017eite\u013e registr\u00e1cie uprav\u00ed po\u017eadovan\u00fa v\u00fd\u0161ku \u00fahrady tak, aby sp\u013a\u0148ala krit\u00e9ri\u00e1 n\u00e1kladovej efekt\u00edvnosti.<\/p>\n\n\n\n

          NIHO z\u00e1rove\u0148 odpor\u00fa\u010da zv\u00e1\u017ei\u0165 preformulovanie indika\u010dn\u00e9ho obmedzenia kv\u00f4li lep\u0161ej zrozumite\u013enosti.<\/p>","protected":false},"excerpt":{"rendered":"

          NIHO odpor\u00fa\u010da vyhovie\u0165 \u017eiadosti o kategorizovanie lieku Jardiance v predmetnej indik\u00e1ci\u00ed, pokia\u013e…<\/p>","protected":false},"author":3,"featured_media":1958,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[11],"tags":[139,138],"class_list":["post-1957","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sumar-hodnotenia","tag-empagliflozin","tag-jardiance"],"_links":{"self":[{"href":"https:\/\/www.niho.sk\/en\/wp-json\/wp\/v2\/posts\/1957","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.niho.sk\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.niho.sk\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.niho.sk\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.niho.sk\/en\/wp-json\/wp\/v2\/comments?post=1957"}],"version-history":[{"count":0,"href":"https:\/\/www.niho.sk\/en\/wp-json\/wp\/v2\/posts\/1957\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.niho.sk\/en\/wp-json\/wp\/v2\/media\/1958"}],"wp:attachment":[{"href":"https:\/\/www.niho.sk\/en\/wp-json\/wp\/v2\/media?parent=1957"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.niho.sk\/en\/wp-json\/wp\/v2\/categories?post=1957"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.niho.sk\/en\/wp-json\/wp\/v2\/tags?post=1957"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}